NanoVibronix posts $458K Q3 revenue; CMS reimbursement request not approved

ENvue Medical, Inc.

Q3 2023 revenue of $458,000; operating loss of $670,000; year-to-date revenue up 22%, operating loss reduced ~20%.
Raised $4.2M net from securities sales; cash & receivables $3.8M, inventory >$3.1M.
UK NHS supply contract and Drug Tariff reimbursement effective Nov 1; UK distributor Peak Medical pursuing opportunities.
Added Mio-Guard as exclusive distributor for Sports segment; VA and Workers Comp channels progressing.
CMS denied full reimbursement again after August 2023 notification; company awaiting response after meeting with CMS leadership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.